Prostate Disorders

Clinical Framework and Screening Guidance

Prostate disorders are among the most common clinical presentations in primary care for adult and older adult men. These include benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. For the FNP exam, understanding the differentiation of symptoms, appropriate screening guidelines, and evidence-based management is high-yield. The U.S. Preventive Services Task Force (USPSTF) and the American Urological Association (AUA) provide key guidance on screening and treatment.^[1][2]

Essential Terminology and Foundational Terms

• Benign Prostatic Hyperplasia (BPH): Non-malignant enlargement of the prostate gland due to hyperplasia of stromal and epithelial cells, commonly causing lower urinary tract symptoms (LUTS).^[3]
• Prostatitis: Inflammation of the prostate gland, which may be acute bacterial, chronic bacterial, or chronic pelvic pain syndrome (CP/CPPS).^[4]
• Prostate Cancer: Adenocarcinoma arising from prostate epithelial cells; often slow-growing but can be aggressive.
• Prostate-Specific Antigen (PSA): A glycoprotein produced by prostate epithelium; used as a tumor marker for screening and monitoring prostate cancer.
• Digital Rectal Exam (DRE): Physical examination of the prostate via the rectum to assess size, consistency, and presence of nodules or tenderness.

Clinical Presentation and Diagnostic Approach

Benign Prostatic Hyperplasia (BPH)

• Pathophysiology: Androgen-driven hyperplasia in the transition zone of the prostate, leading to bladder outlet obstruction.
• Common symptoms: Hesitancy, weak stream, frequency, urgency, nocturia, incomplete bladder emptying.
• Assessment: Use AUA Symptom Index (AUA-SI) to quantify severity.^[3]
• Diagnostic workup: Urinalysis, serum PSA, DRE, and in selected cases uroflowmetry or post-void residual (PVR).

Prostatitis

• Acute bacterial prostatitis: Sudden onset of fever, chills, perineal pain, dysuria, and urinary retention.
• Chronic bacterial prostatitis: Recurrent urinary tract infections with persistent low-grade symptoms.
• Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): Pelvic pain ≥3 months without evidence of infection.
• Diagnosis: Urine culture, expressed prostatic secretion (EPS) culture, and pre- and post-massage urine tests (Meares-Stamey 4-glass test).^[4]

Prostate Cancer

• Risk factors: Age (>50), African American race, family history (first-degree relative), BRCA mutations.
• Screening: Shared decision-making for men aged 55–69 per USPSTF; use PSA with or without DRE.^[1]
• Diagnostic confirmation: Transrectal ultrasound-guided biopsy (TRUS biopsy) with Gleason grading.
• Staging: Uses TNM classification and risk stratification (low, intermediate, high).

Comparative Symptomatology and Physical Exam Findings

Screening Strategies and Diagnostic Reasoning

PSA Screening Controversy

• USPSTF recommends individualized decision for men 55–69 years (Grade C). Men ≥70 should not be screened (Grade D).^[1]
• PSA >4.0 ng/mL is often used as cut-off, but age-adjusted levels are recommended.
• Free PSA ratio: A lower percentage (<10%) increases suspicion of prostate cancer.

Differential Diagnosis

• All three disorders can present with LUTS. Red flags for cancer: hard nodule, elevated PSA, rapid progression, bone pain.
• Prostatitis vs. BPH: Presence of infection (fever, positive culture) points to prostatitis.

Therapeutic Management and Patient Education

BPH Management

1. Watchful waiting for mild symptoms (AUA-SI 0–7).
2. Pharmacotherapy: Alpha-1 blockers (tamsulosin, alfuzosin), 5-alpha-reductase inhibitors (finasteride, dutasteride).
3. Combination therapy for moderate-severe symptoms.
4. Minimally invasive procedures: Transurethral resection of the prostate (TURP) for refractory cases.

Educate patient: Avoid decongestants, limit caffeine and alcohol, void regularly.^[3]

Prostatitis Management

• Acute bacterial: Antibiotics (fluoroquinolones, TMP-SMX) for 4–6 weeks; alpha-blockers for retention.
• Chronic bacterial: Prolonged antibiotics (up to 12 weeks) based on culture.
• CP/CPPS: Multimodal – alpha-blockers, anti-inflammatory drugs, pelvic physiotherapy, cognitive behavioral therapy.^[4]

Prostate Cancer Management

• Active surveillance for low-risk disease.
• Treatment options: Radical prostatectomy, radiation therapy, brachytherapy, androgen deprivation therapy (ADT).
• Chemotherapy for metastatic castration-resistant prostate cancer.
• Side effect management: Erectile dysfunction (PDE5 inhibitors), urinary incontinence (pelvic floor exercises).

Risk Management and Adverse Event Prevention

• Acute urinary retention in BPH – requires catheterization; avoid bladder overdistension.
• Sepsis in acute prostatitis – monitor for signs of worsening infection; hospitalize if systemically ill.
• Bone metastasis from advanced prostate cancer – may cause pathologic fractures or spinal cord compression (emergency).
• DRE caution: Can cause transient PSA elevation; defer blood draw for PSA before DRE.
• Medication safety: Alpha-blockers can cause orthostatic hypotension; 5-ARIs may lower PSA (must adjust interpretation).

Test Preparation Strategies and High-Yield Review

• Know the AUA symptom index – used to categorize mild (0–7), moderate (8–19), severe (20–35).
• PSA derivative concepts: PSA density, velocity, free-to-total ratio – testable on exams.
• First-line BPH treatment: For moderate symptoms – alpha blocker (tamsulosin) is typical starting point.
• Prostatitis antibiotic duration: Acute 4 weeks, chronic 6–12 weeks. Fluoroquinolones are preferred.
• Prostate cancer screening age 55–69 – shared decision making for USPSTF; for high-risk (African American, family history) start at 45.
• Mnemonics: BPH symptoms (Hesitancy, Intermittency, Nocturia, Urgency, Weak stream, Straining, Incomplete emptying) – common exam list.
• DRE findings: Enlarged but smooth = BPH; tender = prostatitis; hard nodule = cancer.

References & Sources

1. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(19):1901-1913. doi: 10.1001/jama.2018.3710
2. American Urological Association. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline (2022). Available at: https://www.auanet.org/documents/Guidelines/PDF/Localized%20Prostate%20Cancer%20Guideline.pdf
3. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803. doi: 10.1016/j.juro.2011.01.074
4. Bowen DK, Dielubanza E, Schaeffer AJ. Chronic bacterial prostatitis and chronic pelvic pain syndrome. BMJ. 2015;350:h833. doi: 10.1136/bmj.h833